2007, Pharmacy and Testimonials - Drug Discovery Digest

The FDA and Feasible Alternative Designs

Drug & Device Law

FEBRUARY 20, 2023

In at least the short term, a popular pain reliever would have to be removed from pharmacies. 7, 2022), which addressed the same question in the context of the admissibility of expert testimony. Therefore, Davis excluded as “not relevant” expert testimony about non-FDA-approved alternatives. This would run counter to. . .

FDA

FDA FDA Approval Testimonials Vaccine

Drug Discovery Digest

The FDA and Feasible Alternative Designs

Webinars

Stay Connected